TY  - JOUR
AU  - Perić, Aleksandar
AU  - Vezmar-Kovačević, Sandra
AU  - Barac, Aleksandra
AU  - Gacesa, Dejan
AU  - Perić, Aneta
AU  - Matković-Jozin, Svjetlana
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3352
AB  - Background: Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs). Aim/objective: To compare effect of hypertonic (2.3% NaCl) sea water and isotonic 0.9% NaCl on symptoms and endoscopic findings in those patients in the period of 1 month after endoscopic sinus surgery (ESS). Material and methods: This prospective, randomized study included 30 patients with aspirin-induced CRS undergoing ESS. Patients were divided into two groups of 15 subjects and one of the two nasal irrigation solutions was administered in each group. Intensity of 5 symptoms (nasal obstruction, nasal discharge/postnasal drip, facial pain/pressure, headache and trouble sleeping) and endoscopic findings were assessed during the 1st, 7th, 14th, 21st and 28th days after the nasal packs removal. Results: We found significantly lower total symptom score (TSS) during the 7th (p= .009), 14th (p = .003), 21st (p  lt  .001) and the 28th day (p=.001), lower total endoscopic score (TES) on the 21st (p = .002) and 28th day (p = .001), lower nasal obstruction, facial pain/pressure, headache and trouble sleeping, and lower nasal mucosal edema, nasal secretion and nasal crusting in patients treated by hypertonic sea water. Conclusion and significance: Hypertonic sea water should be recommended douching solution in the early postoperative care of patients with aspirin-induced CRS.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Acta Oto-Laryngologica
T1  - Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery
VL  - 139
IS  - 6
SP  - 529
EP  - 535
DO  - 10.1080/00016489.2019.1605454
ER  - 

@article{
author = "Perić, Aleksandar and Vezmar-Kovačević, Sandra and Barac, Aleksandra and Gacesa, Dejan and Perić, Aneta and Matković-Jozin, Svjetlana",
year = "2019",
abstract = "Background: Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs). Aim/objective: To compare effect of hypertonic (2.3% NaCl) sea water and isotonic 0.9% NaCl on symptoms and endoscopic findings in those patients in the period of 1 month after endoscopic sinus surgery (ESS). Material and methods: This prospective, randomized study included 30 patients with aspirin-induced CRS undergoing ESS. Patients were divided into two groups of 15 subjects and one of the two nasal irrigation solutions was administered in each group. Intensity of 5 symptoms (nasal obstruction, nasal discharge/postnasal drip, facial pain/pressure, headache and trouble sleeping) and endoscopic findings were assessed during the 1st, 7th, 14th, 21st and 28th days after the nasal packs removal. Results: We found significantly lower total symptom score (TSS) during the 7th (p= .009), 14th (p = .003), 21st (p  lt  .001) and the 28th day (p=.001), lower total endoscopic score (TES) on the 21st (p = .002) and 28th day (p = .001), lower nasal obstruction, facial pain/pressure, headache and trouble sleeping, and lower nasal mucosal edema, nasal secretion and nasal crusting in patients treated by hypertonic sea water. Conclusion and significance: Hypertonic sea water should be recommended douching solution in the early postoperative care of patients with aspirin-induced CRS.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Acta Oto-Laryngologica",
title = "Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery",
volume = "139",
number = "6",
pages = "529-535",
doi = "10.1080/00016489.2019.1605454"
}

Perić, A., Vezmar-Kovačević, S., Barac, A., Gacesa, D., Perić, A.,& Matković-Jozin, S.. (2019). Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. in Acta Oto-Laryngologica
Taylor & Francis Ltd, Abingdon., 139(6), 529-535.
https://doi.org/10.1080/00016489.2019.1605454

Perić A, Vezmar-Kovačević S, Barac A, Gacesa D, Perić A, Matković-Jozin S. Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. in Acta Oto-Laryngologica. 2019;139(6):529-535.
doi:10.1080/00016489.2019.1605454 .

Perić, Aleksandar, Vezmar-Kovačević, Sandra, Barac, Aleksandra, Gacesa, Dejan, Perić, Aneta, Matković-Jozin, Svjetlana, "Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery" in Acta Oto-Laryngologica, 139, no. 6 (2019):529-535,
https://doi.org/10.1080/00016489.2019.1605454 . .

TY  - JOUR
AU  - Perić, Aleksandar
AU  - Vezmar-Kovačević, Sandra
AU  - Gacesa, Dejan
AU  - Perić, Aneta
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2868
AB  - Objective: Herbal medicinal products have a well-established role in therapy of upper airway inflammations. Current evidence supports the use of intranasal corticosteroids for improvement in clinical symptoms of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate efficacy and safety of combined therapy by mometasone furoate nasal spray (MFNS) and oral herbal medicinal product Sinupret in comparison to MFNS monotherapy when treating mild to moderate ARS. Methods: Forty-six ARS patients were divided into two groups. Group 1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily and MFNS 200 mu g twice daily for 7 days. Group 2 (n=23) received only MFNS 200 mu g twice daily for 7 days. We assessed total symptom score (TSS), individual symptom scores for each symptom (nasal obstruction, rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell) and endoscopic findings (mucosal edema, mucopurulent secretion), before and after treatment. Results: Significant improvement of all clinical parameters was found after both treatment modalities (p lt 0.000). We observed lower post-treatment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001), facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema (p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret group than in MFNS group. We found no adverse events in MFNS/Sinupret group, while only 1 patient reported mild epistaxis and 1 patient reported dryness in the nose in MFNS Group. Conclusion: Our results suggest better efficacy of combined MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic findings, with the absence of adverse events in comparison to MFNS monotherapy.
PB  - Deomed Publ, Istanbul, Istanbul
T2  - ENT Updates
T1  - Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray
VL  - 7
IS  - 2
SP  - 68
EP  - 74
DO  - 10.2399/jmu.2017002003
ER  - 

@article{
author = "Perić, Aleksandar and Vezmar-Kovačević, Sandra and Gacesa, Dejan and Perić, Aneta",
year = "2017",
abstract = "Objective: Herbal medicinal products have a well-established role in therapy of upper airway inflammations. Current evidence supports the use of intranasal corticosteroids for improvement in clinical symptoms of uncomplicated acute rhinosinusitis (ARS). We aimed to evaluate efficacy and safety of combined therapy by mometasone furoate nasal spray (MFNS) and oral herbal medicinal product Sinupret in comparison to MFNS monotherapy when treating mild to moderate ARS. Methods: Forty-six ARS patients were divided into two groups. Group 1 (n=23) received herbal drug Sinupret, 160 mg per os, three times daily and MFNS 200 mu g twice daily for 7 days. Group 2 (n=23) received only MFNS 200 mu g twice daily for 7 days. We assessed total symptom score (TSS), individual symptom scores for each symptom (nasal obstruction, rhinorrhea, postnasal drip, facial pain/pressure, impaired sense of smell) and endoscopic findings (mucosal edema, mucopurulent secretion), before and after treatment. Results: Significant improvement of all clinical parameters was found after both treatment modalities (p lt 0.000). We observed lower post-treatment TSS (p=0.002), nasal obstruction (p=0.001), rhinorrhea (p=0.001), facial pain (p=0.001), impaired sense of smell (p=0.002), mucosal edema (p=0.003) and mucopurulent secretion (p=0.001) in MFNS/Sinupret group than in MFNS group. We found no adverse events in MFNS/Sinupret group, while only 1 patient reported mild epistaxis and 1 patient reported dryness in the nose in MFNS Group. Conclusion: Our results suggest better efficacy of combined MFNS/Sinupret therapy of ARS on nasal symptoms and endoscopic findings, with the absence of adverse events in comparison to MFNS monotherapy.",
publisher = "Deomed Publ, Istanbul, Istanbul",
journal = "ENT Updates",
title = "Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray",
volume = "7",
number = "2",
pages = "68-74",
doi = "10.2399/jmu.2017002003"
}

Perić, A., Vezmar-Kovačević, S., Gacesa, D.,& Perić, A.. (2017). Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray. in ENT Updates
Deomed Publ, Istanbul, Istanbul., 7(2), 68-74.
https://doi.org/10.2399/jmu.2017002003

Perić A, Vezmar-Kovačević S, Gacesa D, Perić A. Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray. in ENT Updates. 2017;7(2):68-74.
doi:10.2399/jmu.2017002003 .

Perić, Aleksandar, Vezmar-Kovačević, Sandra, Gacesa, Dejan, Perić, Aneta, "Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray" in ENT Updates, 7, no. 2 (2017):68-74,
https://doi.org/10.2399/jmu.2017002003 . .